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ABSTRACT 
Impaired canalicular secretion due to increased endocytosis and intracellular retention of 
canalicular transporters such as BSEP and MRP2 is a main, common pathomechanism of 
cholestasis. Nevertheless, the mechanisms governing this process are unknown. We characterized 
this process in estradiol 17 β-D-glucuronide (E17G)-induced cholestasis, an experimental model 
which partially mimics pregnancy-induced cholestasis. Inhibition of clathrin-mediated endocytosis 
(CME) with monodansylcadaverine (MDC) or K
+
 depletion, but not the caveolin-mediated 
endocytosis inhibitors filipin and genistein, prevented E17G-induced endocytosis of BSEP and 
MRP2, and the associated impairment of activity of these transporters in isolated rat hepatocyte 
couplets (IRHC). Immunofluorescence and confocal microscopy studies showed that, in E17G-
treated IRHC, there was a significant increase in the colocalization of MRP2 with clathrin, AP2, 
and Rab5, three essential members of the CME machinery. Knockdown of AP2 by siRNA in 
sandwich-cultured rat hepatocytes completely prevented E17G-induced endocytosis of BSEP and 
MRP2. MDC significantly prevented this endocytosis, and the impairment of bile flow and biliary 
secretion of BSEP and MRP2 substrates, in isolated and perfused livers. BSEP and MRP2, which 
were mostly present in raft (caveolin-enriched) microdomains in control rats, were largely found 
in non-raft (clathrin-enriched) microdomains in livers from E17G-treated animals, from where 
they can be readily recruited for CME. In conclusion, our findings show that CME is the 
mechanism responsible for the internalization of the canalicular transporters BSEP and MRP2 in 
E17G-induced cholestasis. The shift of these transporters from raft to non-raft microdomains 
could be a prerequisite for the transporters to be endocytosed under cholestatic conditions. 
 
 
Keywords: canalicular transporters; clathrin-mediated endocytosis; estrogen-induced cholestasis; 
lipid rafts.  
 
Abbreviations: BS, bile salts; BSEP, bile salt export pump; MRP2, multidrug resistance-
associated protein 2; E17G, estradiol 17 β-D-glucuronide; EE, 17α-ethynylestadiol; IRHC, isolated 
rat hepatocyte couplets; CME, clathrin mediated endocytosis; MDC, monodansylcadaverine; 
siRNA, small interfering RNA; SCRH, sandwich cultured rat hepatocytes; IPL, isolated and 
perfused livers; TC, taurocholate; DNP-SG, dinitrophenyl glutathione; cVA, canalicular vacuolar 
accumulation; CGamF, cholyl-glycylamidofluorescein; GS-MF, glutathione methylfluorescein. 
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1. INTRODUCTION 
Bile formation is an osmotic-driven process that involves the concentrative canalicular 
excretion of osmotically active biliary solutes, such as bile salts (BS) and glutathione. Therefore, 
two of the most relevant canalicular transporters involved in bile formation are the BS export 
pump (BSEP) which transports monoanionic BS, and multidrug resistance-associated protein 2 
(MRP2) which transports glutathione and glutathione conjugates, besides a wide variety of anionic 
compounds. 
Under physiological conditions, canalicular transporters undergoes constitutive 
internalization to a subapical vesicular compartment, which constitute a reservoir of transporters 
available for targeting to the apical domain on demand [1]. It has been demonstrated that 
constitutive endocytosis of BSEP is mediated by clathrin-coated vesicles; a conserved sequence in 
its C-terminal domain, which is characteristic to all ABC transporters, is indispensable for this 
process [2]. Internalization of BSEP is therefore sensitive to the treatment with chlorpromazine, an 
inhibitor of clathrin-mediated endocytosis (CME) [3]. On the other hand, the formation of MRP2-
containing vesicles from the canalicular membrane is mediated by dynamin, an essential 
component of clathrin-dependent and independent endocytosis, but not by clathrin [3]. 
Under cholestatic conditions, the physiological recycling of these transporters is altered, 
leading to a decrease in their expression at the canalicular membrane and an increase in 
intracellular, vesicular compartments. This exacerbated endocytic internalization has been 
described in several experimental and clinical types of cholestasis, and was systematically 
associated with a failure in the secretion of the specific substrates of BSEP and MRP2; 
accordingly, this process is considered crucial for the pathogenesis of the cholestatic disease [4]. 
Estradiol 17 β-D-glucuronide (E17G) is an endogenous metabolite of estradiol whose plasma 
levels increase during pregnancy and was postulated as responsible for the pathogenesis of 
intrahepatic cholestasis of pregnancy as well as that associated to hormonal replacement therapy in 
susceptible women [5]. Administration of E17G to rats produces a dose-dependent, acute and 
reversible cholestasis, and it is considered an excellent, reproducible experimental model of 
cholestasis in general, and of pregnancy-induced cholestasis in particular [6]. 
Our group demonstrated that endocytosis of BSEP and MRP2 induced by E17G depends on 
the activation of critical signaling pathways, including “classical” (Ca+2-dependent) protein kinase 
C (PKC) isoforms (cPKC) [7], phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) [8], 
mitogen-activated protein kinases (MAPKs) of the p38
MAPK
 and extracellular signal related kinase 
(ERK)1/2 types [9], estrogen receptor alpha (ER-α) [10], EGFR-Src [11], and GPR30-adenylyl 
cyclase-PKA [12]. The cPKC/ER-α/EGFR/p38MAPK-signaling pathway plays a critical role in the 
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initial endocytic internalization of canalicular transporters that leads to cholestasis [7,9,10], 
whereas PI3K/Akt/ERK1/2 is responsible for maintaining canalicular transporters internalized [7–
10].  
In spite of the enormous progress made in the acknowledgment of the signaling pathways 
leading to the endocytosis and intracellular retention of canalicular transporters in cholestasis 
induced by E17G, the molecular mechanisms governing the endocytic process remain unknown, 
and their characterization represented the main aim of this work. 
 
2. MATERIALS AND METHODS 
2.1. Animals 
Adult female Wistar rats were maintained on a standard laboratory diet and water ad libitum 
and housed in a temperature- and humidity-controlled environment under a constant 12-h 
light/dark cycle. All animals received humane care, according to the Guide for the Care and Use 
of Laboratory Animals (National Institutes of Health). Protocols were approved by the local 
animal welfare committee. 
 
2.2 Experimental procedures and treatments 
Isolated rat hepatocyte couplets (IRHC) were obtained as previously described [13]. To 
ascertain the role for clathrin on BSEP and MRP2 endocytosis, IRHC were pre-incubated with the 
inhibitor of CME, monodansylcadaverine (MDC, Sigma-Aldrich, 100 µM, 15 min) [14]. 
Additionally, CME was inhibited by a K
+
 depletion protocol [15]. Briefly, IRHC were exposed to 
a hypotonic shock (L15/water, 1:1) for 5 min, and then incubated for 30 min in minimal media (20 
mM Hepes at pH 7.5, 140 mM NaCl, 1 mM CaCl2, 1 mM MgSO4, 5.5 mM glucose and 0.5% 
BSA); control buffer was supplemented with 10 mM KCl. The caveolin dependence was 
ascertained by using filipin (Sigma-Aldrich, 10 µg/mL, 15 min), a cholesterol-binding agent that 
prevents caveolae vesicle formation and, at the concentration used here, inhibited endocytosis in 
the hepatocyte-derived human cell line HepG2 [16]; additionally, caveolin-dependent endocytosis 
was inhibited with genistein (Sigma-Aldrich, 200 µM, 15 min) [17]. After this pretreatments, 
IRHC were exposed to E17G (200 µM), or vehicle (dimethyl sulfoxide, DMSO) in controls, for 20 
min. 
Freshly isolated rat hepatocytes, obtained as previously described [18] were treated with small 
interfering RNA (siRNA) targeting AP2, and cultured in collagen sandwich configuration (SCRH) 
to allow a polarized conformation, as described [10]. After 72h, SCRH were treated with E17G 
(200 µM; 30 min), or vehicle in controls. 
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For synthesis of siRNA to inhibit AP2 function, four RNA duplexes (siRNA) targeting to 
mRNA of rat adaptor AP2 subunit µ1 (siRNA1, CATGCCTGCCATGCGCTTG), subunit µ2 
(siRNA2, TTGACGCGAAAGGCATCCA), subunit α1 (siRNA3, 
CTGGCCAGTGTGCACATGCT) and subunit α2 (siRNA4, TTTCCCTTTAATTTGTAGG) were 
designed with WIsiRNA selection program [19]. The siRNA control was designed by scrambling 
the nucleotides of one of these specific targets. siRNAs were synthesized with Ambion’s Silencer 
siRNA Kit (Ambion, Cambridge, MA). 
In isolated and perfused livers (IPL), the perfusion protocol was as described [7]. Taurocholate 
(TC, 2.5 µM) and 1-chloro-2,4-dinitrobenzene (0.5 µM) were added to the perfusion medium for 
BS and dinitrophenylglutathione (DNP-SG) biliary secretion studies. After a 15-min equilibration 
period, MDC (100 µM), or its vehicle (DMSO) in controls, was added to the reservoir. Fifteen min 
later, a 5-min basal bile sample was collected, followed by an intraportal single injection (over a 
1-min period) of E17G (2 µmol/liver, in 10% BSA in saline) or only the vehicle in controls, and 
bile was collected at 5-min intervals for an additional 20-min period.  
In experiments involving whole animals, E17G (15 µmol/kg of b.w., in DMSO-10 % BSA in 
saline) was administered by femoral vein, and liver samples were taken after 20 min of E17G 
administration. 
 
2.3. Assessment of BSEP and MRP2 secretory function 
Functional changes in BSEP and MRP2 in IRHC under the treatments described above were 
evaluated by assessing the canalicular vacuolar accumulation (cVA) of cholyl-
glycylamidofluorescein (CGamF), a fluorescent Bsep substrate, or glutathione methylfluorescein 
(GS-MF), a fluorescent Mrp2 substrate derived from 5- chloromethylfluorescein diacetate, as 
described [12]. Briefly, cells were exposed to 2 µM CGamF or 2.5 µM CMFDA for 15 min, and 
canalicular transport activity was assessed by quantifying the percentage of IRHC in the field 
displaying in their canalicular vacuoles enough fluorescent signal to make it visible under an 
inverted fluorescence microscope (Zeiss Axiovert 25), from a total of 250-300 couplets per 
preparation. 
Functional status of MRP2 in SCRH was evaluated by assessing the initial transport rate (ITR) 
of GS-MF, as described [20]. This parameter is the slope of the initial linear phase of canalicular 
accumulation of this fluorescent substrate, assessed by quantitative time-lapse imaging, under an 
inverted fluorescence microscope [20]. 
In IPL, transport activities of BSEP and MRP2 were evaluated by measuring biliary TC and 
DNP-SG excretion, respectively. DNP-SG content was assessed in all samples by high-
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
6 
 
performance liquid chromatography, using authentic standards. Total bile salt concentration was 
assessed using the 3α-hydroxysteroid dehydrogenase procedure, and the result was assumed as TC 
concentration.  
 
2.4. Assessment of BSEP and MRP2 subcellular localization 
To evaluate the intracellular distribution of BSEP and MRP2 after treatments, IRHC and SCRH 
were fixed, permeabilized, and incubated with antibodies against BSEP (Cat. # PC-064, Kamiya 
Biomedical Company, 1:100, 1 h) or MRP2 (M2III-6, Alexis Biochemicals, 1:100, 1 h), followed 
by incubation with the respective Cy2-conjugated secondary antibodies (Jackson 
ImmunoResearch, 1:200, 2 h). Canaliculi were delimited by staining pericanalicular F-actin with 
Alexa Fluor 568 phalloidin (Molecular Probes, 1:100, 2 h). For colocalization studies, IRHC and 
SCRH were incubated with the Ab to MRP2 and Abs to Rab5, AP2, clathrin or caveolin (Cell 
Signaling, 1:100, 1 h), followed by incubation with the secondary antibodies, as described above. 
Nuclei were stained with 1.5 μM 4,6-diamidino-2-phenylindole. 
In whole animals and IPL experiments, a liver lobe was excised 20 min after E17G 
administration, frozen immediately in liquid nitrogen-precooled isopentane, and stored at -70°C, 
for further immunofluorescence and confocal microscopy analysis, as described previously [7].  
Densitometric analysis of transporter distribution from confocal images was carried out along a 
line perpendicular to the canalicular vacuole (in IRHC samples), or to the canaliculi (in liver 
samples), using the ImageJ software, in an investigator-blinded fashion, as previously described 
[7]. 
For colocalization studies, confocal Z-stack images were obtained in control and E17G-treated 
IRHC and SCRH. The images were analyzed using the ImageJ software. AP2, Rab5, clathrin or 
caveolin positive structures in each single image were demarcated by setting a threshold in the 
corresponding channel to these proteins to define a mask. The fraction of MRP2 that localized at 
these structures was estimated by measuring the total intensity of fluorescence in the images 
generated by applying the logical function “AND” between the MRP2 image and the AP2, Rab5, 
clathrin or caveolin mask. The percentage of MRP2 that colocalized with each protein was 
calculated relating the total intensity of fluorescence at the AP2, Rab5, clathrin or caveolin 
positive structures for MRP2 to the corresponding total cell fluorescence. The inverse analysis, 
i.e., setting of the threshold on the images to define a mask for MRP2, followed by the above 
described procedure, was performed to estimate the percentage of total cell AP2, Rab5, clathrin or 
caveolin colocalizing with MRP2.  
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2.5. Preparation of detergent soluble and insoluble plasma membrane fractions  
From liver homogenates, fractions enriched in plasma membranes were prepared by 
ultracentrifugation at 200,000g for 60 min on a discontinuous 1.3 mol/L sucrose gradient, as 
described [21,22]. Lack of contamination of these membrane fractions with microsomal 
membranes had been previously demonstrated by assessing the enzymatic activity of the hepatic 
subcellular markers, 5´-nucleotidase (plasma membrane), acid phosphatase (lysosomes), aspartate 
aminotransferase (mitochondria), and glucose-6-phosphatase (microsomes) [21,22]. To further 
confirm the purity of the plasma membranes obtained, we assessed by western blot the expression 
of the early and recycling endosomal markers, Rab5 and Rab11, respectively, and they were 
virtually absent of this fraction (data not shown). 
Purified plasma membranes thus obtained were resuspended in buffer (20 mM Tris-HCl [pH 
7.4], 150 mM NaCl, 1 mM ethylene diamine tetraacetic acid (EDTA), and a mixture of protease 
inhibitors), containing 1% (final concentration) Triton X-100 (Sigma-Aldrich), and incubated on 
ice for 30 min. Insoluble components were spun down at 18,000g for 60 min, and the supernatant 
(containing Triton X-100 soluble proteins) were collected in a new tube. The pellets were 
resuspended in solubilization buffer (50 mM Tris-HCl [pH 8.8], 5 mM EDTA, and 1% sodium 
dodecyl sulfate) and homogenized. After acetone precipitation, soluble (non-raft microdomains) 
and insoluble (raft microdomains) fractions were processed for western blotting [23]. 
 
2.6. Immunoblotting 
Western blots of membrane fractions were performed by using the previously described 
antibodies to BSEP, MRP2, caveolin-1, mouse β-actin and clathrin, and the corresponding 
horseradish peroxidase-conjugated secondary antibodies (Thermo Scientific, Rockford, IL). 
Protein bands were detected by an enhanced chemiluminescence detection system (Thermo 
Scientific). Autoradiographs were obtained by exposing the membranes to Amersham Hyperfilm 
ECL (GE Healthcare Limited, Chalfont St. Giles, UK). Densitometric analysis of the developed 
bands was performed using ImageJ Software. 
 
2.7. Statistical analysis 
One-way ANOVA, followed by Newman-Keuls’ test, was used for multiple comparisons. The 
variances of the densitometric profiles of BSEP and MRP2 localization were compared with the 
Mann–Whitney U test. Values of p < 0.05 were considered to be statistically significant.  
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3. RESULTS 
3.1. Impairment of secretory function and localization of BSEP and MRP2 induced by E17G 
in IRHC is prevented by inhibitors of CME 
Transport activity of BSEP and MRP2 in IRHC was evaluated by analyzing the cVA of their 
fluorescent substrates CGamF and GS-MF, respectively. The decrease in cVA of CGamF and GS-
MF induced by E17G was prevented by the specific inhibition of CME in IRHC pre-treated either 
with MDC or with a K
+ 
depletion protocol. In contrast, in IRHC pre-treated with filipin or 
genistein, two specific inhibitors of caveolin-mediated endocytosis, a significant decrease in the 
cVA of both fluorophores was observed, similar to that induced by E17G (Figure 1).  
Figure 2A shows representative confocal images showing that E17G induced a redistribution of 
the canalicular transporters MRP2 and BSEP (green) from the canalicular zone (delimited by the 
pericanalicular actin network, in red) into intracellular vesicles (white arrows). This phenomenon 
was totally prevented by the blockade of the CME with MDC. This was confirmed by 
densitometric analysis of the fluorescence associated with the transporters (Figure 2B). None of 
the treatments modified actin distribution (Figure 2B). MDC itself did not modify the normal 
distribution of the transporters (data not shown). 
 
3.2. E17G increases the colocalization of MRP2 with proteins involved in CME 
Representative confocal images of the colocalization of clathrin (A), AP2 (B), and Rab5 (C) 
with MRP2 in IRHC and SCRH are shown in Figures 3 and 4, respectively.  
In the color panels of Figure 3, depicting the merge between MRP2 staining and clathrin, AP2, 
and Rab5 masks, respectively, it can be observed that, under E17G treatment, MRP2 increases its 
colocalization with these proteins, mainly in the zone where intracellular vesicles are localized 
(amplified insets). Quantitative analysis confirmed a significant increase in the percentage of 
colocalization between MRP2 and these proteins in the E17G group (bar plots on the right). The 
percentage of clathrin, AP2, and Rab5 colocalizing with MRP2 was also increased when we 
performed the reverse analysis, i.e., colocalization of clathrin, AP2, and Rab5 with MRP2 mask 
(data not shown). Like happened in IRHC, in SCRH, the colocalization of these proteins with 
MRP2 was significantly higher under E17G treatment, as compared with the control (Figure 4A, 
B, and C). On the other hand, colocalization of caveolin with MRP2 showed an important 
decrease in E17G-treated IRHC (Figure 3D).  
For colocalization studies, both antibodies to the transporters (BSEP and MRP2) and the 
proteins of interest must be developed in different hosts. Since no commercial mouse antibodies to 
rat clathrin, Rab5, and AP2 are available, we bought the only commercial mouse antibody with 
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reported reactivity to rat BSEP [BSEP (F-6) antibody, sc-74500, Santa Cruz Biotechnology], but 
we failed to obtain positive immunofluorescent staining of BSEP using this antibody.  
 
3.3. AP2 knock-down inhibits the endocytosis of BSEP and MRP2 induced by E17G 
AP2 plays a crucial role in the machinery of CME. In order to confirm our findings using 
inhibitors of this endocytic pathway, the effect of E17G on the localization of BSEP and MRP2 
was evaluated in SCRH transfected with siRNA targeting to rat AP2 mRNA. Experiments of 
knock down of AP2 with siRNA were performed in SCRH since this primary culture remains 
viable for a time period that allows the siRNA to silence the gene of interest. Unlike the IRHC 
model, the SCRH model also gives a protein yield that allows protein expression detection by 
western blot. Four different siRNAs were tested and siRNA1, which induced the more significant 
decrease in AP2 protein expression, was chosen for function and localization studies (Figure 5A). 
Supporting a crucial role for AP2 in E17G-induced endocytosis of canalicular transporters, 
confocal images of the transfected SCRH show that the alteration in the localization of MRP2 and 
BSEP induced by E17G (Figure 5B, white arrows) were prevented in those cells effectively 
transfected with the siRNA against the AP2 µ1-adapting subunit. Besides, the knock-down of AP2 
prevented the functional alteration of MRP2 induced by E17G, as assessed by the ITR of GS-MF, 
reaching transport values not significantly different from control SCRH (Figure 5C). On the other 
hand, in SCRH treated with E17G, the ITR of GS-MF decreased approximately 50% as compared 
to controls. 
 
3.4. MDC prevents biliary secretory alterations and the endocytosis of BSEP and MRP2 
induced by E17G in IPL 
Administration of E17G to IPL produces a decrease in BF to approximately 40% of basal 
values (Figure 6A). This decrease is accompanied by a significant diminution in the biliary 
excretion of the substrates of MRP2 (Figure 6B) and BSEP (Figure 6C), DNP-SG (40% of basal) 
and TC (70% of basal), respectively. The activity of both transporters begins to recover after 15 
min of E17G administration. In IPL pre-treated with MDC, the alteration in BF and TC excretion 
induced by E17G was partially but significantly prevented, while the alteration produced in the 
excretion of DNP-SG was totally prevented (Figure 6). 
In IPL treated with E17G, both transporters are detected in intracellular structures, compatible 
with endocytic vesicles (Figure 7A, white arrows). This internalization was prevented in those IPL 
that were perfused with MDC, which showed a similar pattern of distribution to control. The 
densitometric studies of the images show that, under treatment with E17G, the distribution curve 
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of the transporters becomes flatter and wider, due to the increase of transporter-associated green 
fluorescence in a farthest zone from the canalicular membrane (Figure 7B). In IPL perfused with 
MDC and treated with E17G, the distribution pattern of both transporters was similar to control. 
None of the treatments modified the canalicular structure, evaluated by occludin distribution. 
MDC per se did not induce changes in the distribution of the transporters (data not shown). 
 
3.5. E17G alters the distribution of BSEP and MRP2 between rafts and non-raft 
microdomains  
BSEP and MRP2 are mostly found in rafts under normal conditions [24]. In fact, there is a 
positive correlation between membrane cholesterol content and the activity of both BSEP and 
MRP2 [25]. CME occurs from non-raft microdomains, which possess the machinery necessary for 
this mechanism. Therefore, for E17G to induce CME of transporters, they should be enriched in 
non-raft microdomains. To verify this contention, raft (high cholesterol) and non-raft (low 
cholesterol) plasma membrane microdomains were isolated based on their differential detergent 
solubility, and their purity was assessed by performing western blot of the raft-marker protein 
caveolin-1 and the non-raft-marker protein clathrin, as described in Materials and Methods and 
shown in Figure 8A.  
BSEP and MRP2 were found enriched in raft microdomains (60% BSEP, 75% MRP2), both 
under basal conditions and after 20 min of vehicle injection in controls. However, in those rats 
who were injected with E17G, a switch of these transporters occurred in the membrane 
microdomains, leading to their enrichment in non-raft microdomains; BSEP was expressed 22% in 
rafts and 78% in non-rafts, while MRP2 was expressed approximately 18% and 82% in rafts and 
non-rafts, respectively (Figure 8B and C). 
 
4. DISCUSSION 
Exacerbated endocytosis of canalicular transporters with intracellular retention in endosomal 
compartments has been reported in numerous experimental cholestatic conditions, and, more 
importantly, in several human cholestatic pathologies [4]. Although this mechanism has been 
recognized as a causal phenomenon leading to impaired canalicular secretion, the molecular 
mechanisms triggering it, as well as the endocytic machinery involved, are still unknown. In this 
work, we gathered evidence demonstrating that, in E17G-induced cholestasis, the canalicular 
transporters BSEP and MRP2 undergo exacerbated endocytic internalization by CME, and that 
this could be associated with a shift of transporters from caveolin-enriched plasma membrane 
microdomains (rafts) to clathrin-enriched ones (non-rafts). 
Several lines of evidence in different models for the study of bile secretion have been provided 
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here for the selective involvement of clathrin, but not caveolin, in E17G-induced BSEP/MRP2 
endocytosis, namely 1) Inhibition of caveolin-dependent endocytosis with filipin was without 
effect; filipin sequesters cholesterol from lipid rafts, and cholesterol is required for caveolae to 
form [26]; 2) different maneuvers leading to CME blockage by unrelated mechanisms, such as 
administration of MDC or K
+
 depletion in IRHC (or the first in IPL); MDC is a potent inhibitor of 
transglutaminase, a cross-linking enzyme necessary for clustering of the endocytosed protein in 
the region of clathrin-coated membrane regions and in the coated pits [27], whereas K
+
 depletion 
induces drastic changes in the distribution of clathrin by removing plasma membrane-associated 
clathrin lattices into "microcages" beneath the plasma membrane [28]; 3) Inhibition of E17G-
induced canalicular transporter internalization was also apparent when CME was blocked by 
knocking down μ1-subunit of AP2 with siRNA; AP2 is an adaptor complex that triggers formation 
of the clathrin lattice, and mediates interaction between clathrin and the cargo protein [29]; 4) 
After being endocytosed, MRP2 colocalized with clathrin, AP2, as well as with Rab5; this small 
GTPase regulates not only the dynamic of early endosome where cargo is sorted after CME but 
also fusion of clathrin-coated vesicles with these early endosomes [30]. 
The clathrin dependence of BSEP and MRP2 endocytosis in E17G-induced cholestasis is 
somewhat unexpected due to the preferential normal localization of these transporters in raft 
microdomains, which are enriched in caveolin rather than clathrin [24,25]. However, the 
preferential association of a plasma membrane protein with rafts is not a determinant of their 
endocytosis via the caveolin-dependent mechanism [31]. Actually, BSEP is constitutively 
internalized via CME, with its C-terminal tyrosine motif (conserved in all the members of the 
ABC superfamily) being key for interaction with AP2 [2]. Furthermore, silencing AP2 expression 
in 3xFlag-BSEP-expresing HeLa cells and in human SCRH inhibited internalization of BSEP [32], 
and in vivo studies demonstrated that constitutive BSEP internalization was inhibited after 
pharmacological impairing of the expression of AP2 α- and μ2-adaptin subunits with 4-
phenylbutyrate in rat and human liver [33]. 
The mechanisms underlying constitutive MRP2 internalization are far less studied, but the 
studies carried out suggested a differential behavior with BSEP. In the T-Rex 293 cell line from 
embryonic human kidney with both BSEP and MRP2 expressed ad hoc, BSEP, but no MRP2 
endocytosis, was sensitive to the inhibitor of CME chlorpromazine [3]. MRP2 was instead 
sensitive to dynasore, a dynamin inhibitor; dynamin play a role both in coated pit scission and in 
linking internalization and actin cytoskeleton in both clathrin-dependent and independent 
endocytosis [34]. If these results would be valid for hepatocytes, and extrapolated to rat MRP2, 
they would suggest that constitutive endocytosis of MRP2 would be different from the endocytosis 
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under cholestasis conditions. 
CME requires the interaction of the protein to be endocytosed with AP2, an interaction that is 
usually done through tyrosine or leucine motifs present at the N or C-terminal domains of the 
endocytosed protein [35], as described for the constitutive endocytosis of BSEP. Lack of clathrin 
dependence of constitutive MRP2 endocytosis suggests that AP2-interaction domains could not be 
present in its structure, thus not allowing its recruitment under physiological conditions. However, 
it is possible that, in a cholestatic context, activation of signaling pathways that have MRP2 as a 
target could induce postransductional modifications on the transporter, which can make possible 
the establishment of unconventional interactions with clathrin. Supporting this possibility, it has 
been recently reported that CME of the K
+
 Kv1.3 channel in HeLa cells depends on its C-terminal 
domain phosphorylation mediated by ERK1/2, after activation of this kinase by EGF [36]. 
Alternatively, it could be possible that E17G induces the endocytosis of MRP2 by a non-
conventional mechanism different from the interaction of AP2 with tyrosine or di-leucine 
domains, interacting through different domains enabled by the phosphorylation of MRP2 through 
one of the pro-cholestatic signaling pathways involved in E17G-induced cholestasis. In line with 
this, a phosphorylation site for PKC, at the C-terminal of MRP2 (Ser
1542
), has been reported [37]. 
Interestingly, different PKC isoforms have been shown by our group and others to be involved in 
the endocytic internalization of MRP2 in different models of cholestasis, including those induced 
by E17G [7], oxidative stress [38], and taurolithocholate [39]. 
In addition, our group has also provided evidence for the participation of p38
MAPK
 in the 
endocytosis of canalicular transporters in E17G-induced cholestasis [9]. This kinase has been 
reported to accelerate CME of several membrane receptors, such as EGFR [40]. Like this, BSEP is 
internalized by CME through a mechanism involving AP2, a protein whose phosphorylation by 
p38
MAPK
 is essential for the recruitment of the cargo towards the clathrin-coated depressions 
during endocytosis of EGFR [41]. Furthermore, another possible target of p38
MAPK
 is Rab-GDP 
(Rab-GDI dissociation inhibitor), a protein that stimulates the recycling of Rab5 between the 
membrane and the cytosol, thereby increasing the endocytic rate [42]. 
Exacerbated CME in cholestasis of transporters that, like BSEP and MRP2, mostly reside in 
rafts microdomains, may involve migration of these transporters to non-rafts microdomains, where 
they can undergo CME. Our results suggest that this could be the case. In line with our finding, 
Marrone et al. have recently reported a similar redistribution of BSEP from raft to non-raft 
microdomains in 17α-ethynylestradiol (EE)-induced cholestasis in rats, and this was suggested to 
contribute to the alteration of BSEP activity in this pathology [23]. Interestingly, our group 
reported that glucuronidation of EE is an essential requirement for it to exert its cholestatic effect 
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[43]. Thus, it is possible to postulate that, in EE cholestasis, its D-ring glucuronide, which is a 
potent acute cholestatic with similar cholestatic mechanisms to E17G [44], is responsible for the 
redistribution of BSEP from raft to non-raft microdomains, and the associated secretory failure 
induced by EE. Suggestively, in EE-induced cholestasis, MRP2 and BSEP decrease their protein 
expression without changes in their mRNA [45,46]. Accordingly, this postrancriptional 
downregulation could be a consequence of the continuous formation of the glucuronide metabolite 
of EE during the 5-day treatment, which would induce a sustained endocytosis of MRP2 and 
BSEP, leading to lysosomal degradation. 
It remains to ascertain the molecular mechanisms by which these metabolites could have 
induced a shift of canalicular transporters between different membrane microdomains. There are 
different ways by which a protein is preferentially integrated into raft microdomains: i) by 
lipidation (protein acylation, glycosylphosphatidylinositol binding or covalent attachment to 
cholesterol), ii) through protein-protein interactions with other proteins anchored to rafts, and iii) 
by having a consensus sequence of amino acid that recognizes and interacts with cholesterol, 
referred to as "CRAC" domain (cholesterol recognition/interaction amino acid consensus). All 
these processes can be, hypothetically, modulated by acute metabolic changes mediated by 
signaling pathways, leading to modifications of the protein-protein interactions or affinity of 
CRAC domains for cholesterol [47]. In transmembrane proteins like transporters, the existence of 
a CRAC domain is the most likely cause of preferential localization in lipid rafts [47]. Although 
the existence of CRAC domains in BSEP and MRP2 has not yet been investigated, five of these 
domains exist in another ABC transporter, BCRP (ABCG2), and they explain the dependence of 
their activity on membrane cholesterol [47]. Bearing in mind that transport activity of both BSEP 
[25] and MRP2 [48] critically depends on the membrane cholesterol content, the existence of 
domains for interaction with cholesterol in their structure is indeed likely. 
Another possible target of E17G that could facilitate the shift of BSEP and MRP2 from raft to 
non-raft microdomains is radixin, a protein of the ERM family that anchors BSEP and MRP2 to 
the canalicular membrane, linking them to the actin cytoskeleton. Disorganization of radixin 
occurs in EE cholestasis and, since EE glucuronide is the causative agent in this pathology, it is 
possible that the same holds true for E17G cholestasis. In general terms, maintenance of lipid and 
protein compartmentalization in raft and non-raft microdomains depends crucially on the integrity 
of the actin cytoskeleton, whose depolymerization leads to homogenization of the plasma 
membrane [49]. Disruption of the hepatocellular distribution of ezrin (a member of the ERM 
family) by keratin 8 knockdown was associated with profound changes in the organization of 
membrane rafts, and in a redistribution of FasR, a protein located in raft microdomains [50]. The 
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raft microdomains themselves (including their lipid components) become more mobile when the 
binding of some of their constituent proteins to the actin cytoskeleton is lost, as has been shown 
for Cbp/PAR protein [51]. 
Migration from raft to non-raft microdomains can also affect the intrinsic activity of 
transporters that may be temporarily retained in this microenvironment. For instance, BSEP 
activity is positively related to the cholesterol content in the membrane, and therefore BSEP 
activity is much higher in rafts, where the carrier is enriched under physiological conditions [25]. 
Therefore, BSEP shift from rafts to non-raft lipid microdomains, as shown here for E17G and 
previously for EE by Marrone et al [23], may represent itself a novel cholestatic mechanism that 
impairs BSEP intrinsic activity, complementary to the exacerbation of BSEP endocytosis induced 
by the same shift, which reduces the density of the carrier in the canalicular membrane. 
Interestingly, bile salt excretion via BSEP was restored by anchoring the transporter to raft 
microdomains via hepatic gene transfer of human aquaporin-1 to these microdomains in the 
canalicular membrane of EE cholestatic rats [23], thus highlighting the crucial impact that 
migration from rafts to non-rafts microdomains have for BSEP function in cholestasis. In contrast, 
MRP2 activity appears to be less influenced by the lipid microenvironment, as suggested by 
studies in HepG2 showing that its transport function depends on membrane cholesterol content but 
not on its presence in detergent-resistant microdomains [48]. This differential effect could explain 
why the inhibition of CME in IPL did not completely prevent the decrease in bile salt excretion 
induced by E17G, as did it for the MRP2 substrate DNP-SG (see Fig 5B). Another possible factor 
that could explain the selective inhibition of BSEP by E17G in MDC-treated IPL is the well-
recognized transinhibition of BSEP by E17G, once excreted into the canaliculus via MRP2 [52]; in 
our model, where the inhibition of the transport function of MRP2 by E17G is completely 
prevented by MDC, such a transinhibition would be fully operative. 
 
5. CONCLUSION 
Our findings clearly demonstrate that CME is the mechanism responsible for the internalization 
of the canalicular transporters BSEP and MRP2 in E17G-induced cholestasis (Figure 9). In 
addition, we provided the first line of evidence of changes in the distribution of these transporters 
in membrane microdomains that could justify, at least partially, the increase of their endocytosis in 
this and possibly in other models of cholestasis. Clearly, further studies are needed to confirm and 
clarify the mechanisms that affect the localization of these transporters in their membrane 
microdomains, as well as the signaling pathways that trigger this process. Irrespective of these 
limitations, the generalized occurrence of canalicular transporter internalization as a 
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physiopathological mechanism in most types of experimental and clinical cholestasis points 
clathrin and other components of CME machinery as new potential targets for future 
pharmacological strategies in cholestasis therapeutics. 
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FIGURE LEGENDS 
 
Figure 1: Effect of clathrin- or caveolin-dependent endocytosis inhibitors on the canalicular 
vacuolar accumulation (cVA) of GS-MF (MRP2 substrate, panel A) and CGamF (BSEP 
substrate, panel B). IRHC were pre-incubated for 15 min with vehicle (in control) or maneuvers 
leading to inhibition of different endocytic pathways, i.e., MDC exposure (100 µM, 15 min) and 
K
+ 
depletion protocol for the clathrin-mediated pathway, and filipin exposure (10 µg/µL, 15 min) 
or genistein incubation (200 µM, 15 min) for the caveolin-mediated ones. Then, IRHC were 
exposed to E17G for a further 20-min period. cVA was calculated from microphotographs, as the 
percentage of IRHC with visible fluorescence in their canalicular vacuoles, with respect to the 
total IRHC present in each field, and referred to control values. Under control conditions, 65-70% 
of the IRHC analyzed were positive for vacuolar fluorescent signal, depending on the preparation. 
Data are expressed as mean ± S.D. (n = 250/300 IRHC per preparation, from at least 3 
independent experiments). *Significantly different from control (p <0.05). 
#
Significantly different 
from genistein group. 
 
Figure 2: MDC prevents the endocytosis of the canalicular transporters MRP2 and BSEP 
induced by E17G in IRHC. A. Representative confocal images of IRHC showing the distribution 
of transporters (green) and the pericanalicular actin network (red). In control conditions, the 
fluorescence associated with the transporters is mostly localized in the canalicular zone. E17G 
(200 µM) induces internalization of these transporters, visualized in vesicles beyond the actin 
limits (white arrows). A similar pattern of transporter internalization was observed in IRHC pre-
treated with filipin (25 µg/mL), and then incubated with E17G. The effect of E17G was 
significantly prevented by pre-treatment with MDC (100 µM). B. Densitometric analysis of 
images was performed along a line perpendicular to the canalicular vacuole (4 µM to each side of 
the vacuole center), by using ImageJ software. A schematic representation of this procedure is 
shown (inset), where the center of the canalicular vacuole is represented by a dotted line. The 
limits of the canalicular space were identified by F-actin-associated fluorescence (B, right). Each 
profile was normalized to the sum of all intensities of the respective measurement. Under E17G 
treatment, these profiles were wider and flatter, compatible with an increment in transporter-
associated fluorescence beyond the limits of the canalicular vacuole. Statistical analysis of the 
differences in the distribution patterns revealed a significant internalization of transporters under 
E17G treatment (p < 0.05 vs. control), which was completely abolished by MDC (p < 0.05 vs. 
E17G). None of the treatments affected the normal distribution of actin. Results are expressed as 
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mean ± S.E.M. n = 6–8 randomly selected canalicular vacuoles per preparation, from 3 
independent preparations. 
 
Figure 3: Colocalization of MRP2 with proteins involved in clathrin-dependent endocytic 
machinery in IRHC. Double immunofluorescent labeling of MRP2 (green) and clathrin (A, red), 
AP2 (B, red), Rab 5 (C, red) or caveolin (D, red) was performed in IRHC. Confocal z-stacks of 
control IRHC and those treated with E17G (200 µM, 20 min) were taken. E17G treatment did not 
affect clathrin, AP2, Rab5 and caveolin cellular distribution. Amplified images of the 
pericanalicular region with clathrin (A), AP2 (B), Rab5 (C), caveolin (D), and MRP2 in 
monochrome, and the merge between MRP2 and each of these proteins in color, are shown; in 
these insets, it can be observed an increment in the colocalization of MRP2 with clathrin, AP2, 
and Rab5 (visualized as yellow staining), as well as a decrease in colocalization between MRP2 
and caveolin (D), in E17G-treated IRHC. Colocalization analysis of the stacks was performed 
with the Image J software. AP2, Rab5, clathrin, or caveolin positive structures were demarcated 
by setting a threshold to define a mask. The fraction of MRP2 that localized at these structures 
was estimated by measuring the total intensity of fluorescence in the images generated by 
applying the logical function “AND” between the MRP2 image and the AP2, Rab5, clathrin, or 
caveolin mask. In E17G-treated IHRC, a higher percentage of colocalization of MRP2 with the 
proteins involved in CME (bar plots in A, B, and C) and a decrease in the colocalization of MRP2 
with caveolin (bar plot in D) was observed. Results are expressed as mean ± S.D. *p <0.05 vs 
control, n = 10 from 3-5 different independent preparations. Scale bar = 3 µm. 
 
Figure 4: Colocalization of MRP2 with proteins involved in clathrin-dependent endocytic 
machinery in SCRH. Double immunofluorescent labeling of MRP2 (green) and clathrin (A, red), 
AP2 (B, red), or Rab 5 (C, red) was performed in SCRH. Confocal z-stacks of control SCRH and 
those treated with E17G (200 µM, 20 min) were taken. E17G treatment did not affect clathrin, 
AP2, and Rab5 cellular distribution, while endocytosis of MRP2 can be clearly visualized. In 
representative images of the overlapping between the MRP2 and the proteins of interest, it can be 
observed an increase in the colocalization of MRP2 with all these proteins in the pericanalicular 
zone under E17G treatment (insets). Colocalization analysis of the stacks was performed with the 
Image J software. In SCRH treated with E17G, a higher percentage of colocalization MRP2 with 
the proteins involved in CME was observed (bar plots). Results are expressed as mean ± S.D. *p 
<0.05 vs. control, n = 10 from 3-5 different independent preparations. Scale bar = 10 µm. 
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Figure 5: Knock down of AP2 in SCRH prevents impairment of localization and transport 
activity of MRP2 induced by E17G. SCRH were transfected with AP2 siRNA and RNA SC for 
48 h. A. Representative western blot of AP2 in transfected SCRH. siRNA 1, 2, and 3 induced a 
significant decrease of AP2 expression. Results are expressed as mean ± S.D. * p < 0.05 vs. SC, n 
= 3. B. Representative confocal images showing the distribution of MRP2 (green) in SCRH under 
different treatments. The canalicular zone is delimited by occludin (red) and the nuclei are shown 
in blue. In scrambled control (SC)-treated SCRH, the fluorescence associated with the transporter 
is confined to the canalicular space. E17G induced a clear internalization of vesicles containing 
the transporter beyond the canalicular limits in these cells (white arrows). In cells transfected with 
siRNA1 and treated with E17G, the internalization was clearly prevented. The siRNA per se had 
no effect on the distribution of MRP2 (data not shown). C. Initial transport rate (ITR) of the 
MRP2 substrate GS-MF. After transfection for 48hs, SCRH were exposed for 30 min to E17G 
(200 µM), or its vehicle in controls, and then to 5-chloromethylfluorescein diacetate, a GS-MF 
precursor. The slope of the curve obtained by plotting the fluorescence intensity associated with 
GS-MF of 70-100 pseudo-canaliculi vs. time from 3 different preparations was used to estimate 
ITR of GS-MF, which was corrected by canalicular width. Data were expressed as mean ± S.D. *p 
<0.05 vs. SC. 
 
Figure 6: MDC prevents alteration of biliary flow and biliary excretion of MRP2 and BSEP 
substrates induced by E17G in IPL. The graphs show the temporal changes in biliary flow (A), 
and biliary excretion of DNP-SG (B) and TC (C), during the perfusion period. IPL were treated 
with a single bolus dose of E17G (2 µmol/liver), or its vehicle in controls, in the presence or 
absence of MDC (200 µM) in the perfusion medium. E17G was administered after 15 min of 
perfusion with MDC or its vehicle, and bile was collected for an additional 20-min period. DNP-
SG and TC biliary excretions were calculated as the product between bile flow and biliary 
concentration of these compounds, and then referred to basal values. Data are expressed as mean ± 
S.D. *Significantly different from control. 
#
Significantly different from MDC + E17G (p <0.05; n 
= 3 animals per group).  
 
Figure 7: MDC prevents E17G-induced endocytosis of BSEP and MRP2 in IPL. A. 
Representative confocal images of BSEP and MRP2 under the different treatments. BSEP (green) 
and occludin (red) are shown in the upper images, and MRP2 (green) and occludin (red) in the 
lower ones. In control IPLs, both transporters are circumscribed to the canalicular space, which 
was delineated by occludin staining. E17G induced a clear internalization of vesicles containing 
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the transporters beyond the limits of the canaliculi (arrows), and this phenomenon was 
significantly prevented by a pre-treatment with MDC (100 µM, 15 min prior to E17G bolus, and 
maintained throughout the perfusion period). MDC per se does not produce any change in the 
location of transporters. B. Densitometric analysis of the fluorescence intensity profile associated 
with BSEP, MRP2 and occludin. Densitometric analysis of images was performed along a line 
perpendicular to the canalicular vacuole (4 µM to each side of the vacuole center), by using 
ImageJ software. A schematic representation of this procedure is shown (inset), where the 
canalicular center is represented by a dotted line. The limits of the canalicular space were 
identified by occludin-associated fluorescence (B, right). Each profile was normalized to the sum 
of all intensities of the respective measurement. The internalization of transporters induced by 
E17G resulted in a decrease in the fluorescence intensity associated with the transporters in the 
canalicular area (flattening of the curve), associated with an increase of it at a greater distance 
from the canaliculus (widening of the curve). Statistical analysis of the profiles revealed a 
significant internalization of transporters under E17G treatment (p < 0.01 vs. control). This 
internalization was completely abolished by MDC (p < 0.01 vs. E17G, n = 20-50 canaliculi per 
preparation, from 3 independent preparations). None of the treatments affected the normal 
distribution of actin. Data are expressed as mean ± S.E.M. 
 
Figure 8: E17G induced a redistribution of BSEP and MRP2 in raft and non-raft 
microdomains. Liver samples were taken at time 0 and 20 min after injecting E17G, or its vehicle 
in controls. Raft and non-raft fractions were obtained from highly purified plasma liver 
membranes. A. Representative western blot for caveolin-1 (raft marker), clathrin (non-raft 
marker), BSEP and MRP2 on raft and non-raft microdomains. B. Distribution of BSEP in rafts 
and non-rafts. C. Distribution of MRP2 in rafts and non-rafts. Data are expressed as mean ± S.D., 
n = 3 from 3 independent experiments. *p <0.05 vs. control (basal and 20 min). 
 
Figure 9: Schematic representation displaying the main findings of this work. BSEP and 
MRP2, are mainly localized in cholesterol- and caveolin-enriched "raft" microdomains under 
physiological conditions. Under a cholestatic insult induced by E17G, the transporters would shift 
from the "raft" to "non-raft" microdomains, where they can be endocytosed via the clathrin-
mediated pathway. This process involves interaction of the transporters with the adaptor protein 
AP2, which triggers clathrin-dependent endocytosis. Endocytosed transporter-containing vesicles 
traffic to apical early endosomes (AEE), from where they can either traffic to Rab11-positive 
apical recycling endosomes (ARE) or being sorted to lysosomal and/or proteasomal degradation. 
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In addition, E17G prevents ARE from trafficking to the apical membrane, so that the transporters 
are retained in this intracellular compartment. 
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Highlights 
E17G-induced endocytosis of BSEP/MRP2 depends on clathrin, but not caveolin. 
Knock down of the clathrin adaptor AP2 blocks E17G-induced BSEP/MRP2 endocytosis. 
E17G increases colocalization of BSEP/MRP2 with clathrin, AP2 and Rab5. 
E17G induces a shift of BSEP/MRP2 from raft to non-raft membrane microdomains. 
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